In the fight against the corona pandemic, according to a media report, the German government is neglecting the development of drugs to treat Covid-19. Since the beginning of the pandemic in Germany, of around one billion euros earmarked for research into means to combat Covid-19, only around 17.5 million has been estimated for drug research, as researched by the broadcaster RBB for “ARD Extra” on Tuesday revealed.
This emerges from the data from the Federal Ministry of Education and Research (BMBF), which ARD has. Researchers at the Charité Clinic in Berlin see their work being slowed down by the lack of federal support. The funding programs advertised by the Federal Research Ministry are not sufficient, they criticize. “We would have wished that (…) more financial resources had been available, then we would be a giant step further in terms of the clinical development of effective therapies,” said gastroenterologist Frank Tacke.
Internationally, according to RBB research, Germany is not in the top field in drug research, unlike in vaccines. Only 102 studies on new drugs are therefore being pursued in this country. In France, on the other hand, there are 234 and in the USA even 768 studies.
It is true that the BMBF launched a new program for drug research in January. But the 50 million earmarked for this is not enough, according to researchers. The development of a single drug alone can cost twice the funding amount